CapsoVision, Inc. (Ticker: CV US) is a US company specializing in commercial-stage medical technology, developing capsule endoscopy solutions that use advanced imaging and artificial intelligence to identify gastrointestinal tract abnormalities. CapsoVision plans to list on NASDAQ on July 1, 2025, offering 5.25 million shares at a price range of $5.00 to $5.50 to raise approximately $28 million. The company has a proposed market capitalization of $242 million. CapsoVision reportedly plans to use the IPO proceeds to grow its sales and marketing team, fund research and development for future products, including an AI-assisted update to its CapsoCam Plus system, and for working capital.